MORPHOLOGICAL AND EXPRESSION FEATURES OF DUCTAL PANCREATIC ADENOCARCINOMA
https://doi.org/10.21294/1814-4861-2017-16-4-26-31
Abstract
Pancreatic cancer is one of the most unfavorable malignancies. Approximately 20 % of patients with pancreatic cancer have resectable disease at the time of diagnosis, however the prognosis of the disease in these patients remains poor, and the overall 5-year survival rate is only 5 %. The evaluation of morphological features, as well as features of the expression of markers that determine the invasive potential of such neoplasms, can serve in the future as a fundamental basis in solving problems concerning prognostic factors in pancreatic cancer. The purpose of the study was to evaluate morphological and immunohistochemical features of pancreatic ductal adenocarcinoma. Material and methods. The study included 84 patients with stage T1–4N0–2M0–1 pancreatic cancer. The age range was from 37 to 83 years. Surgery was the main treatment option. Morphological examination of surgical specimens showed that the tumor histotype corresponded to pancreatic ductal adenocarcinoma. The preparation of histological specimens and immunohistochemical staining were carried out according to standard procedures. Results and conclusion. This study allowed us to determine the features of tumor morphology, as well as the features of expression of markers associated with more pronounced invasive properties of the tumor. The results of this study may be of interest in terms of their further comparison with the parameters of various forms of progression in pancreatic cancer.
About the Authors
Yu. Yu. Rakina
Siberian Federal Scientific-Clinical Center of the Federal Medical-Biological Agency.
Russian Federation
Rakina Yulia Yu., MD, Surgery Department, Siberian Federal Scientific-Clinical Center of the Federal Medical-Biological Agency. 4, Mira Str., 634003-Seversk, Tomsk region, Russia.
Russian Federation
Rakina Yulia Yu., MD, Surgery Department, Siberian Federal Scientific-Clinical Center of the Federal Medical-Biological Agency. 4, Mira Str., 634003-Seversk, Tomsk region, Russia.
M. V. Zavyalova
Siberian State Medical University; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.
Russian Federation
Russian Federation
Zavyalova Marina V., MD, Professor, Head of Pathological Anatomy Department of Siberian State Medical University; Senior Researcher of the Department of Pathological Anatomy and Cytology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.
2, Moskovsky tract, 634050-Tomsk, Russia.
N. V. Krakhmal
Siberian State Medical University; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.
Russian Federation
Russian Federation
Krakhmal Nadezhda V., MD, PhD, Pathological Anatomy Department, Siberian State Medical University, Department of Pathological Anatomy and Cytology.
5, Kooperativny Str., 634009-Tomsk, Russia.
A. P. Koshel
Siberian State Medical University.
Russian Federation
Russian Federation
Koshel Andrey P., MD, Professor, Head of the Department of surgery with the course of mobilization training and medicine of accidents, Siberian State Medical University.
2, Moskovsky tract, 634050-Tomsk, Russia.S. G. Afanasyev
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.
Russian Federation
Russian Federation
Afanasyev Sergey G., MD, DSc., Leading Researcher, Thoracic and Abdominal Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Science.
5, Kooperativny Str., 634009-Tomsk, Russia.
S. V. Vtorushin
Siberian State Medical University; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.
Russian Federation
Russian Federation
Vtorushin Sergey V., MD, Professor, Pathological Anatomy Department, Siberian State Medical University; Senior Researcher of the Department of Pathological Anatomy and Cytology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences.
2, Moskovsky tract, 634050-Tomsk, Russia.
References
1. Kimura K., Amano R., Nahata B., Yamazoe S., Hirata K., Murata A., Miura K., Nishio K., Hirakawa T., Ohira M., Hirakawa K. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol. 2014 Nov 27; 12: 360. doi: 10.1186/1477-7819-12-360.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb; 62 (1): 10–29. doi: 10.3322/caac.20138.
3. Zuckerman D.S., Ryan D.P. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008 Jan 15; 112 (2): 243–9.
4. Gerry J.M., Poultsides G.A. Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection. Dig Dis Sci. 2017 Jul; 62 (7): 1816–1826. doi: 10.1007/s10620-017-4570-6.
5. Weinberg B.A., Philip P.A., Salem M.E. Evolving standards of care for resected pancreatic cancer. Clin Adv Hematol Oncol. 2017 Feb; 15(2): 141–150.
6. Riediger H., Keck T., Wellner U., zur Hausen A., Adam U., Hopt U.T., Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009 Jul; 13 (7): 1337–44. doi: 10.1007/s11605-009-0919-2.
7. Sierzega M., Popiela T., Kulig J., Nowak K. The ratio of metastatic/resected lymph node is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas. 2006 Oct; 33 (3): 240–5.
8. Zacharias T., Jaeck D., Oussoultzoglou E., Neuville A., Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007 Mar; 11 (3): 350–6.
9. Lim J.E., Chien M.W., Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003 Jan; 237 (1): 74–85.
10. Schnelldorfer T., Ware A.L., Sarr M.G., Smyrk T.C., Zhang L., Qin R., Gullerud R.E., Donohue J.H., Nagorney D.M., Farnell M.B. Long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008 Mar; 247 (3): 456–62. doi: 10.1097/SLA.0b013e3181613142.
11. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO Classification of Tumours of the Digestive System. World Health Organization. 2010; 417.
12. Rebrova О.Yu. Statistical analysis of medical data. The use of STATISTICA software. Мoscow, 2002; 312. [in Russian]
13. Principe M., Borgoni S., Cascione M., Chattaragada M.S., Ferri-Borgogno S., Capello M., Bulfamante S., Chapelle J., Di Modugno F., Defilippi P., Nisticò P., Cappello P., Riganti C., Leporatti S., Novelli F. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017; 10 (1): 16. doi: 10.1186/s13045-016-0385-8.
14. Rebelo T.M., Chetty C.J., Ferreira E., Weiss S.F. Anti-LRP/LRspecific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells. BMC Cancer. 2016 Nov 24; 16 (1): 917.
15. Krakhmal N.V., Zavyalova M.V., Denisov E.V., Perelmuter V.M., Vtorushin S.V. Cancer invasion: patterns and mechanism. Acta Naturae. 2015 Apr-Jun; 7 (2): 17–28.
16. Topalovski M., Brekken R.A. Matrix control of pancreatic cancer: New insights into fibronectin signaling. Cancer Lett. 2016 Oct 10; 381 (1): 252–8. doi: 10.1016/j.canlet.2015.12.027.
Review
For citations:
Rakina Yu.Yu., Zavyalova M.V., Krakhmal N.V., Koshel A.P., Afanasyev S.G., Vtorushin S.V. MORPHOLOGICAL AND EXPRESSION FEATURES OF DUCTAL PANCREATIC ADENOCARCINOMA. Siberian journal of oncology. 2017;16(4):26-31. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-26-31
Views:
1574
Email this article 
